GCLLSG Prognostic Index
| . | Score . | 5-y survival, % . |
|---|---|---|
| Biomarker | ||
| Age, y | ||
| ≤60 | 0 | |
| >60 | 1 | |
| Sex | ||
| Female | 0 | |
| Male | 1 | |
| ECOG PS | ||
| 0 | 0 | |
| >0 | 1 | |
| β2-microglobulin, mg/L | ||
| ≤1.7 | 0 | |
| 1.7-3.5 | 1 | |
| >3.5 | 2 | |
| Serum thymidine kinase, U/L | ||
| ≤10 | 0 | |
| >10 | 2 | |
| IGHV | ||
| Mutated | 0 | |
| Unmutated | 1 | |
| 11q22-q23 | ||
| Nondeleted | 0 | |
| Deleted | 1 | |
| 17p13 | ||
| Nondeleted | 0 | |
| Deleted | 6 | |
| Risk group | ||
| Low risk | 1-2 | 95 |
| Intermediate risk | 3-5 | 86 |
| High risk | 6-10 | 67 |
| Very-high risk | 11-14 | 18 |
| . | Score . | 5-y survival, % . |
|---|---|---|
| Biomarker | ||
| Age, y | ||
| ≤60 | 0 | |
| >60 | 1 | |
| Sex | ||
| Female | 0 | |
| Male | 1 | |
| ECOG PS | ||
| 0 | 0 | |
| >0 | 1 | |
| β2-microglobulin, mg/L | ||
| ≤1.7 | 0 | |
| 1.7-3.5 | 1 | |
| >3.5 | 2 | |
| Serum thymidine kinase, U/L | ||
| ≤10 | 0 | |
| >10 | 2 | |
| IGHV | ||
| Mutated | 0 | |
| Unmutated | 1 | |
| 11q22-q23 | ||
| Nondeleted | 0 | |
| Deleted | 1 | |
| 17p13 | ||
| Nondeleted | 0 | |
| Deleted | 6 | |
| Risk group | ||
| Low risk | 1-2 | 95 |
| Intermediate risk | 3-5 | 86 |
| High risk | 6-10 | 67 |
| Very-high risk | 11-14 | 18 |
ECOG PS, Eastern Cooperative Oncology Group performance status; GCLLSG, German CLL Study Group.